Secondary analysis of phase 3 PURPOSE 1: in 487 women aged 16–25 who became pregnant, lenacapavir PrEP vs daily oral emtricitabine-tenofovir had balanced adverse events, similar pregnancy losses, unchanged drug exposure in pregnancy and minimal infant plasma levels.
Secondary analysisn = 487
Bekker et al. HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial